Get the Stockscreener App
39.16
2.82%
-1.135
After Hours:
38.95
-0.215
-0.55%
Celcuity Inc stock is traded at $39.16, with a volume of 1.60M.
It is down -2.82% in the last 24 hours and up +193.37% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$40.30
Open:
$40
24h Volume:
1.60M
Relative Volume:
1.95
Market Cap:
$1.48B
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-14.61
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+178.75%
1M Performance:
+193.37%
6M Performance:
+227.74%
1Y Performance:
+113.67%
1-Day Range:
$38.66
$41.50
1-Week Range:
$13.59
$46.42
52-Week Range:
$7.575
$46.42
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
39.16 | 1.57B | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Resumed | Stifel | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity Raises $248.7 Million Through Stock and Notes - TipRanks
How strong is Celcuity Inc. company’s balance sheetSmart Portfolio Data Feed For 2025 - jammulinksnews.com
Celcuity prices $248.7M debt, stock offerings - MSN
Celcuity Surges 4.68% on $423.7M Capital Raise as $250M Volume Ranks 486th - AInvest
Dalvey David sells Celcuity (CELC) stock worth $4.8 million - Investing.com Australia
Dalvey David sells Celcuity (CELC) stock worth $4.8 million By Investing.com - Investing.com India
Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst - Seeking Alpha
Celcuity Inc. Announces Pricing of Concurrent Public - GlobeNewswire
Celcuity (CELC) Is Up 176.2% After Positive Phase 3 Breast Cancer Results — Has the Bull Case Changed? - simplywall.st
Celcuity Prices Public Offering Of 175 Mln, 2.75% Sr. Notes, And 1.84 Mln Shares At $38/Shr - Nasdaq
Celcuity prices $175 million convertible notes, $85 million stock offering - Investing.com Australia
Celcuity prices $175 million convertible notes, $85 million stock offering By Investing.com - Investing.com Nigeria
Form FWP Celcuity Inc. Filed by: Celcuity Inc. - StreetInsider
Is Celcuity Inc. stock a good hedge against inflationQuick Gain Stock Watch With Indicators Reviewed - metal.it
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments - Benzinga
Up 215% YTD, Should You Grab This Growth Stock Before It’s Too Late? - Barchart.com
AI Trend Models Suggest Bounce for Celcuity Inc.Watchlist for Smart Swing Trading Updated - metal.it
Celcuity's triple drug combo tops AstraZeneca's treatment in breast cancer trial - MSN
Celcuity Shares Double After Landmark Breast Cancer Drug Trial Results - MSN
Relay Therapeutics has positive read from Celcuity data, says Barclays - Yahoo Finance
Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial - Insider Monkey
Celcuity Amends Loan Agreement and Launches Offerings - TipRanks
Celcuity dips premarket after convertible bond, stock offerings unveiled - TradingView
Celcuity stock price target raised to $50 from $27 at H.C. Wainwright - Investing.com
Celcuity: What’s Happening With CELC Stock? - Forbes
Will Celcuity Inc. continue its uptrendLow Drawdown Stock Screener with Analysis - Newser
Celcuity eyes big market opportunity after breast cancer win - pharmaphorum
Price Floor Holding on Celcuity Inc. — Rebound PossibleWeekly Stock Watch With Growth Focus Expanded - metal.it
Will Celcuity Inc. Stock Benefit from AI and Green Energy TrendsEarnings Based Stock Performance Forecast - Newser
Celcuity (NASDAQ:CELC) Given New $50.00 Price Target at HC Wainwright - Defense World
Short Term Trend Reversal in Celcuity Inc. PossibleAI Based High Gain Watchlist Scanner Shared - metal.it
Celcuity (NASDAQ:CELC) Given Buy Rating at Needham & Company LLC - Defense World
Leerink Partners Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price - Defense World
These 10 Stocks are Winning Big - Insider Monkey
Celcuity announces $225M combined offerings; shares down - MSN
Why Celcuity Inc. stock attracts strong analyst attentionFree Stock Screener With Smart Filters - Newser
Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock - GlobeNewswire
Celcuity Preps For Potentially Huge Market After Phase III Gedatolisib Win - insights.citeline.com
Celcuity’s Bold Moves: A Mix of Innovation and Market Strategy - timothysykes.com
Celcuity rockets after positive trial results on breast cancer combo treatment - Sherwood News
Celcuity announces $225 million in proposed public offerings - Investing.com
Geda load of this: Celcuity rocks breast cancer phase III - BioWorld MedTech
Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success - Invezz
Celcuity Inc (CELC) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Celcuity price target raised to $60 from $28 at Leerink - TipRanks
Celcuity stock rallies on Phase III breast cancer trial progress - Yahoo Finance
Celcuity's triple cancer drug combo beats AstraZeneca in halting cancer progression, shows study - Mint
Celcuity shares triple on late-stage results for breast cancer therapy - BioPharma Dive
Celcuity rockets on new gedatolisib data - The Pharma Letter
Celcuity to Present Updated Results for Treatment-Naïve Patients from Phase 1b Study of Gedatolisib at the 2023 ESMO Breast Cancer Annual Congress - ACCESS Newswire
Celcuity Stock (NASDAQ: CELC) shares Skyrockets 210% on Breakthrough Breast Cancer Trial Results | Celcuity Stock Price - paginasiete.bo
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):